Webinar Series
Trends and Updates in IBD
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
Suggested Readings
Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF, et al. Lancet. 2018;390(10114):2779-2789.
Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M, et al. Pharmacol Res. 2013;76:1-8.
Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies.
Kim DH, Cheon JH. Immune Netw. 2017;17(1):25-40.
The future of Janus kinase inhibitors in inflammatory bowel disease.
De Vries LCS, et al. J Crohns Colitis. 2017;11(7):885-893.
JAK inhibition in inflammatory bowel disease.
Olivera P, et al. Expert Rev Clin Immunol. 2017;13(7):693-703.
Tofacitinib as induction and maintenance therapy for ulcerative colitis.
Sandborn WJ, et al. N Engl J Med. 2017;377(5):496-497.
Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Vermeire S, et al. Lancet. 2017;389(10066):266-275.
Linked Resources
Clinical Practice Guidelines
Ulcerative Colitis Care Pathway.
Dassopoulos T, et al. Gastroenterology. 2015;149(1):238-245.
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Peyrin-Biroulet L, et al. Am J Gastroenterol. 2015;110(9):1324-1338.
European Crohn’s and Colitis Organisation
Patient Resources
Inflammatory Bowel Disease (IBD): What Is It?
Crohn’s and Colitis Foundation
Types of Medications for Crohn’s Disease and Ulcerative Colitis
Treatment Decisions
Advocacy Tools and Resources
Crohn’s Disease and Ulcerative Colitis: Emotional Factors Q & A
The National Institute of Diabetes and Digestive and Kidney Diseases Health Information
Related activities
Webcast
0.25 AMA PRA
Trends and Updates in IBD: Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
Snapshot of IBD Today
| Faculty: | Bruce E. Sands, MD, MS; Thomas A. Ullman, MD |
| Release: | 08/23/2019 |
| Expiration: | 08/23/2020 |
Webcast
0.25 AMA PRA
Trends and Updates in IBD: Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
The Current and Emerging Treatment Landscape of IBD
| Faculty: | Bruce E. Sands, MD, MS; Thomas A. Ullman, MD |
| Release: | 08/23/2019 |
| Expiration: | 08/23/2020 |
